Clinical Effect of Bazhen Decoction Combined with Sequential Treatment of Chemotherapy on Acute Lymphoblastic Leukemia Patients with Deficiency of Qi and Yin

Abstract

84 acute lymphoblastic leukemia patients with deficiency of both Qi and Yin treated in the Rizhao Hospital of Traditional Chinese Medicine from January 2014 to October 2016 were selected. According to the method of random control table, the patients were divided into study group and control group, with 42 patients in each group. The patients in the control group was treated by sequentially with standard chemotherapy regimen（VDCLP + intensive chemotherapy）, and the patients in the study group were treated by Bazhen decoction based on control group. The complete remission after 1 month of treatment and 3year followup mortality were compared between the patients in the two groups, the blood routine, the levels of Th17, Th22, Treg and immunoglobulin(IgA, IgG and IgM) in peripheral blood of the patients were detected, the occurrence of myelosuppression and adverse reactions were analyzed. The complete remission rate (90.48% vs 73.81%) after 1 month of treatment, 3year survival rate (71.79% vs 47.37%) and diseasefree survival (61.54% vs 36.84%) of the patients in the study group were significantly higher than those in the control group (P<0.05). After treatment, the levels of granulocytes, WBC, PLT, and Hb of the patients in both of the two groups were increased significantly, and the blood routine test values of the patients in the study group were significantly higher than those in the control group(P<0.05). After treatment, the levels of Th17 and Th22 of the patients in the study group were significantly higher than those in the control group, while Treg was significantly lower than those in the control group (P<0.05). The levels of IgA, IgM and IgE in peripheral blood of the patients in the study group were increased significantly after treatment, and the levels of immunoglobulin of the patients in the study group were significantly higher than those in the control group (P<0.05). The proportion of bone marrow suppression grade 0 of the patients in the study group was significantly higher than those in the control group, while the proportion of grade III was significantly lower than those in the control group, and the overall inhibition degree of the patients in the study group was lighter than those in the control group (P<0.05). The incidence of nausea and vomiting, liver and kidney injury and infection of the patients in the study group was significantly lower than those in the control group (P<0.05). Bazhen decoction can improve the blood routine and immune function of acute lymphoblastic leukemia patients with qiyin deficiency after sequential treatment, reduce bone marrow suppression and the incidence of adverse reactions, thus improving the clinical efficacy.